(Q40220508)

18 September 2017

0 references

Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future? (English)

1 reference

18 September 2017

1

Björn Dahlöf

0 references

Sverre E. Kjeldsen

series ordinal

3

object named as

Sverre E Kjeldsen

1 reference

18 September 2017

2

Richard B Devereux

1 reference

18 September 2017

Paulette A Lyle

4

1 reference

18 September 2017

Zhongxin Zhang

series ordinal

5

1 reference

18 September 2017

Jonathan M Edelman

series ordinal

6

1 reference

18 September 2017

publication date

1 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

16

1 reference

18 September 2017

issue

1

1 reference

18 September 2017

page(s)

6-12

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

β-blockers in hypertension—the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Testing for qualitative interactions between treatment effects and patient subsets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Blood pressure, stroke, and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Overview of the outcome trials in older patients with isolated systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

A meta-analysis of outcome trials in elderly hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F08037050701246386

10.1080/08037050701246386

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference